Alaunos Therapeutics price to book ratio TCRT

Market value divided by the book value of the company's net assets, since 2011.

Today, Oct 23, 2026: 8.9×
8-year median: 3.9×
Against its 8-year history: 88th; percentile: 0 is its lowest day, 100 its highest
8-year range: 0.8× to 54.0×
Peer median: 1.6×

Alaunos Therapeutics' price to book ratio is 8.9× as of Oct 23, 2026.

That is above its 8-year median of 3.9×, higher than on 88% of days in the last 8 years.

Over that time it ranged from 0.8× in Dec 2023 to 54.0× in May 2026.

The median for 3 healthcare stocks of a similar size is 1.6×.

Price to book ratio over time

median 3.9×

The dashed line is the 8-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	8.9×	2.0×	54.0×
2025	2.6×	0.8×	7.9×
2024	1.1×	0.8×	4.3×
2023	1.2×	0.8×	5.4×
2022	4.4×	1.8×	19.9×
2021	3.4×	3.4×	7.9×
2020	3.7×	2.7×	8.0×
2019	8.8×	5.5×	14.4×
2018	n/m a value too high to mean anything
2017	n/m a value too high to mean anything
2016	8.7×	6.9×	13.5×
2015	11.6×	9.8×	47.1×
2014	13.8×	6.5×	110×
2013	99.6×	2.6×	99.6×
2012	5.7×	3.4×	6.3×
2011	3.6×	3.4×	5.4×

Against its peers

Companies in Healthcare nearest Alaunos Therapeutics' size, closest first, today.

Company	Price to book ratio
TCRTAlaunos Therapeutics	8.9×
NEPHNephros	3.2×
ATNMActinium Pharmaceuticals	1.6×
APTAlpha Pro Tech	0.9×
Peer median	1.6×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Alaunos Therapeutics

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.